US FDA accepts and grants priority review status to AstraZeneca & Daiichi Sankyo's BLA for Dato-DXd for patients with previously treated advanced EGFR-mutated NSCLC

Source :: PharmaBiz. January 14, 2025
Publication Year :: 2025
Abstract: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally [...]

Subjects :: AstraZeneca PLC -- Technology application
United States. Food and Drug Administration -- Government finance
Drug therapy
Technology application
Government finance
Durvalumab -- Government finance -- Technology application
Osimertinib -- Technology application -- Government finance
Patient compliance -- Government finance -- Technology application
Epidermal growth factors -- Technology application -- Government finance
Drug approval -- Government finance -- Technology application
Non-small cell lung cancer -- Drug therapy
Cancer metastasis -- Drug therapy
Prescriptions (Drugs) -- Technology application -- Government finance
Metastasis -- Drug therapy
Drugs -- Prescribing
Lung cancer, Non-small cell -- Drug therapy
Epidermal growth factor -- Technology application -- Government finance

Tools